AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

Rhea-AI Summary

AEON Biopharma (NYSE American: AEON) announced it has regained compliance with NYSE American continued listing standards related to stockholders’ equity. NYSE Regulation confirmed that previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide have been resolved, and AEON expects the “.BC” below-compliance indicator to be removed from its Class A common stock.

Compliance was regained after an underwritten public offering closed on July 15, 2026, including 17,851,599 shares of common stock and pre-funded warrants for 24,837,008 shares, plus 4,696,102 additional shares sold on July 23, 2026 via over-allotment. AEON received approximately $13.6 million in net proceeds and may receive up to $34.0 million more upon full cash exercise of milestone warrants, and believes its stockholders’ equity now exceeds the $4.0 million minimum requirement.

Positive

• Regained NYSE American compliance with stockholders’ equity listing standards
• $13.6 million aggregate net proceeds from July 2026 equity offering
• Potential up to $34.0 million additional gross proceeds from milestone warrant exercises
• Stockholders’ equity believed above $4.0 million minimum under Section 1003(a)(ii)

Negative

• Significant issuance of 17.9 million shares plus 24.8 million pre-funded warrants and over-allotment shares causes dilution
• Company remains subject to NYSE American’s standard listing monitoring procedures
• Upcoming June 30, 2026 Form 10-Q will show a stockholders’ deficit before reflecting offering proceeds

News Explained

The closed offering supports listing compliance but increases dilution, while June 30 statements will still show the pre-offering deficit.

The offering is closed, and its issued shares and pre-funded warrants convert into common shares on exercise; those additions reduce existing common holders’ percentage ownership absent offsetting changes.

Because it was underwritten, an investment bank bought the securities from AEON for resale, while underwriting discounts, commissions, and expenses reduced gross proceeds to the reported net amount.

The June 30, 2026 balance sheet in the upcoming unaudited Form 10-Q will still show a stockholders’ deficit and present the offering’s net proceeds as a subsequent event because the offering closed after quarter-end.

At March 31, 2026, AEON reported $6.243 million of cash and equivalents and $2.636 million of quarterly operating cash outflow; that cash balance equaled 213.2 days of the reported cash use.

Sources and calculations

• AEON Biopharma compliance announcement (2026-08-03)
• Dilution definition (undated)
• Underwritten offering definition (undated)
• AEON Biopharma first-quarter 2026 fundamentals (2026Q1)

• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $6,243,000 / ($2,636,000 / 90) = [object Object]

Market Reaction – AEON

-2.55% $0.28

15m delay

-2.55% Vs previous close

+11.8% Peak in 0 min

$0.28 Last Price

$0.26 $0.34 Day Range

$14.26M Market Cap

0.2x Rel. Volume

Following this news, AEON has declined 2.55%, reflecting a moderate negative market reaction. Argus tracked a peak move of +11.8% during the session. Our momentum scanner has triggered 16 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.28.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

AEON’s historical offering event, news_id 1081340, had a 10.84% 24-hour reaction, adding a direct fi...

Analysis

AEON’s historical offering event, news_id 1081340, had a 10.84% 24-hour reaction, adding a direct financing precedent to this compliance announcement. The active S-3 resale registration is a structural risk; subsequent-event equity reporting warrants attention.

Key Figures

Compliance notice date: Aug. 3, 2026 Common shares offered: 17,851,599 shares Pre-funded warrants: 24,837,008 shares +5 more

8 metrics

Compliance notice date Aug. 3, 2026 NYSE American confirmation

Common shares offered 17,851,599 shares Offering closed July 15, 2026

Pre-funded warrants 24,837,008 shares Shares issuable upon warrant purchase

Milestone warrant terms Two-year and five-year warrants Each offering share or pre-funded warrant included both

Over-allotment shares 4,696,102 shares Sold July 23, 2026

Net offering proceeds Approximately $13.6 million Aggregate net proceeds after offering costs

Potential warrant proceeds Up to an additional $34.0 million Gross proceeds upon full cash exercise

Minimum equity requirement $4.0 million NYSE American Section 1003(a)(ii)

Historical Context

5 past events · Latest: Jul 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 14	Public offering	Positive	+10.8%	Upsized offering announced with potential additional funding from milestone warrants
Jun 04	Analytical data	Positive	+0.8%	ABP-450 structural and functional comparability data presented at scientific meeting
May 14	Q1 earnings update	Positive	-9.9%	FDA strategy support and debt reduction accompanied quarterly financial results
Apr 24	Shareholder meeting	Negative	-0.9%	Annual meeting notice included an audit going concern qualification
Apr 03	Leadership change	Positive	+2.4%	CFO appointment and inducement awards included NYSE compliance-linked PSUs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mostly aligned with event direction, with the Q1 earnings update representing the sole divergence.

Key Terms

biosimilar, pre-funded warrants, milestone warrants, underwritten public offering, +2 more

6 terms

biosimilar medical

"advancing ABP-450 as a biosimilar to BOTOX"

A biosimilar is a medicine created to be highly similar to an existing complex drug made from living cells, matching its safety and effectiveness while allowing for small, natural variations. For investors, biosimilars matter because they introduce lower-cost competition when patents end, which can cut prices, shift market share, and change revenue forecasts for companies selling the original drugs, much like a generic version does for simpler chemical medicines.

pre-funded warrants financial

"pre-funded warrants to purchase 24,837,008 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

milestone warrants financial

"accompanied by a two-year milestone warrant"

Milestone warrants are rights that let holders buy a company’s stock only if specific goals—such as regulatory approvals, sales targets, or project completions—are met. Think of them as a coupon that only becomes usable when the company hits agreed checkpoints; they matter to investors because they create contingent value and potential share dilution, and they signal which outcomes the company and its backers consider most important.

underwritten public offering financial

"following completion of its underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

stockholders’ equity financial

"compliance with NYSE American’s continued listing standards relating to stockholders’ equity"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

subsequent event financial

"which will be reflected as a subsequent event"

An event that occurs after a company’s reporting period ends but before its financial statements are issued or finalized, which can change the amounts or disclosures in those statements. Like finding a large unpaid bill after closing a bank statement, these events matter to investors because they can alter a company’s reported performance or risks and therefore affect how current financial figures should be interpreted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX^® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC (“NYSE American”) confirming that AEON has regained compliance with NYSE American’s continued listing standards relating to stockholders’ equity.

On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company had resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). As a result, the Company expects that the “below compliance” (“.BC”) indicator will be removed from the Company’s trading symbol for its Class A common stock (“Common Stock”), and the Company will be removed from NYSE American’s list of noncompliant issuers on its website. The Company will remain subject to NYSE American’s standard listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward.

The Company regained compliance following completion of its underwritten public offering (the “Offering”). On July 15, 2026, the Company closed the Offering of 17,851,599 shares of Common Stock and pre-funded warrants to purchase 24,837,008 shares of Common Stock, with each share of Common Stock or pre-funded warrant accompanied by a two-year milestone warrant to purchase one share of Common Stock and a five-year milestone warrant to purchase one share of Common Stock. On July 23, 2026, the Company sold an additional 4,696,102 shares of Common Stock pursuant to a partial exercise of the underwriters’ over-allotment option. The Company received aggregate net proceeds from the Offering of approximately $13.6 million, after deducting underwriting discounts and commissions and estimated offering expenses, with the potential to receive up to an additional $34.0 million in gross proceeds upon the full cash exercise of the milestone warrants issued in connection with the Offering. As a result of the completed Offering, the Company believes it currently has stockholders’ equity in excess of the $4.0 million minimum requirement under Section 1003(a)(ii) of the Company Guide. Because the Offering closed after the end of the Company’s second fiscal quarter, the unaudited balance sheet as of June 30, 2026, to be included in the Company’s Quarterly Report on Form 10-Q for that quarter will reflect a stockholders’ deficit and will not give effect to the net proceeds of the Offering, which will be reflected as a subsequent event.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX^®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450 for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau^®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s ability to maintain compliance with NYSE American’s continued listing standards, the Company’s product development and regulatory plans, and the Company’s business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to maintain compliance with NYSE American’s continued listing standards; (ii) the Company’s ability to obtain additional and sufficient financing; (iii) the Company’s anticipated financial performance, including cash and cash equivalents; (iv) the Company’s plans regarding any interactions with the U.S. Food and Drug Administration; (v) the outcome of regulatory interactions; and (vi) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.

Investor Contact:

Hershel Berry
Blueprint Life Science Group
Hberry@bplifescience.com

Source: AEON Biopharma

FAQ

What does AEON Biopharma’s (AEON) regained NYSE American compliance mean for its stock?

AEON Biopharma’s regained compliance means its stock again meets NYSE American equity listing standards. According to AEON, deficiencies under Sections 1003(a)(i) and 1003(a)(ii) were resolved, so the “.BC” noncompliance indicator is expected to be removed from its trading symbol.

How did AEON Biopharma (AEON) regain compliance with NYSE American listing standards in August 2026?

AEON Biopharma regained compliance by completing an underwritten public offering that increased stockholders’ equity. According to AEON, the company raised about $13.6 million net and believes equity now exceeds the $4.0 million minimum required under Section 1003(a)(ii) of the Company Guide.

How much capital did AEON Biopharma (AEON) raise in its July 2026 offering?

AEON Biopharma raised approximately $13.6 million in net proceeds from its July 2026 offering. According to AEON, this included 17,851,599 common shares, pre-funded warrants for 24,837,008 shares, and 4,696,102 additional shares sold through a partial over-allotment exercise.

What is the potential additional funding from AEON Biopharma’s (AEON) milestone warrants?

AEON Biopharma may receive up to $34.0 million in additional gross proceeds from milestone warrants. According to AEON, each common share or pre-funded warrant issued in the offering included a two-year and a five-year milestone warrant, exercisable for one share of common stock each.

Will AEON Biopharma’s (AEON) next Form 10-Q show it in compliance with equity requirements?

AEON Biopharma’s June 30, 2026 Form 10-Q will show a stockholders’ deficit, not the post-offering equity. According to AEON, the offering closed after quarter-end, so proceeds will appear as a subsequent event rather than in the balance sheet figures.

Is AEON Biopharma (AEON) still being monitored by NYSE American after regaining compliance?

Yes, AEON Biopharma will remain subject to NYSE American’s standard listing monitoring procedures. According to AEON, although equity-related deficiencies have been resolved, the exchange will continue its usual oversight to ensure ongoing compliance with listing standards.